Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunomodulatory Drugs for the Treatment of B Cell Malignancies
Nikolaos Ioannou, Khushi Jain, Alan G. Ramsay
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 16, pp. 8572-8572
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Reprogramming of Treg cells in the inflammatory microenvironment during immunotherapy: a literature review
Xinyan Wu, Zhigang Zhou, Qiang Cao, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 31
Targeting cereblon in hematologic malignancies
Ota Fuchs
Blood Reviews (2022) Vol. 57, pp. 100994-100994
Open Access | Times Cited: 30
Recent Updates on the Development of Deuterium-Containing Drugs for the Treatment of Cancer
Tafere Mulaw Belete
Drug Design Development and Therapy (2022) Vol. Volume 16, pp. 3465-3472
Open Access | Times Cited: 29
The progress of novel strategies on immune-based therapy in relapsed or refractory diffuse large B-cell lymphoma
Tingxun Lu, Jie Zhang, Zijun Y. Xu‐Monette, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 18
Chimeric Antigen Receptor (CAR)-T Cell Therapy for Non-Hodgkin’s Lymphoma
Maria Florencia Giraudo, Zachary Jackson, Indrani Das, et al.
Pathogens and Immunity (2024) Vol. 9, Iss. 1, pp. 1-17
Open Access | Times Cited: 7
Inside-Out of Complement in Cancer
Martin Kolev, Madhumita Das, Monica Gerber, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 26
Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy
Abigail Colley, Timothy Brauns, Ann E. Sluder, et al.
Trends in Molecular Medicine (2024) Vol. 30, Iss. 8, pp. 765-780
Closed Access | Times Cited: 5
Follicular Lymphoma: Paving the Path to Cures through Philanthropy
Mitchell R. Smith, Michel Azoulay, Lee M. Greenberger
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Efficacy and Safety of Chimeric Antigen Receptor (CAR)-T Cell Therapy in Patients with Non-Hodgkin Lymphoma
Abdur Jamil, Zaheer Qureshi, Rimsha Siddique, et al.
American Journal of Clinical Oncology (2025)
Closed Access
Regulatory T cells (Tregs) in lymphoid malignancies and the impact of novel therapies
Kamira Maharaj, Angimar Uriepero, Eva Sahakian, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 18
Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma
Khalil Saleh, Morgane Cheminant, David Chiron, et al.
Cancers (2022) Vol. 14, Iss. 13, pp. 3229-3229
Open Access | Times Cited: 17
Beyond Bruton’s tyrosine kinase inhibitors in mantle cell lymphoma: bispecific antibodies, antibody–drug conjugates, CAR T-cells, and novel agents
Neeraj Jain, Mukesh Mamgain, Sayan Mullick Chowdhury, et al.
Journal of Hematology & Oncology (2023) Vol. 16, Iss. 1
Open Access | Times Cited: 10
FPFT-2216, a novel anti-lymphoma compound, induces simultaneous degradation of IKZF1/3 and CK1α to activate p53 and inhibit NF-κB signaling
Daiki Kanaoka, Mitsuo Yamada, Hironori Yokoyama, et al.
Cancer Research Communications (2024)
Open Access | Times Cited: 3
Synergy between BRD9- and IKZF3-Targeting as a Therapeutic Strategy for Multiple Myeloma
Basudev Chowdhury, Swati Garg, Wei Ni, et al.
Cancers (2024) Vol. 16, Iss. 7, pp. 1319-1319
Open Access | Times Cited: 3
Hypofractionated radiotherapy combined with lenalidomide improves systemic antitumor activity in mouse solid tumor models
Kateryna Onyshchenko, Ren Luo, Xi Rao, et al.
Theranostics (2024) Vol. 14, Iss. 6, pp. 2573-2588
Open Access | Times Cited: 3
Targeting the tumor microenvironment for treating double-refractory chronic lymphocytic leukemia
Richard Lewis, Alexander F. vom Stein, Michael Hallek
Blood (2024) Vol. 144, Iss. 6, pp. 601-614
Open Access | Times Cited: 3
Pharmacologic targeting of Nedd8-activating enzyme reinvigorates T-cell responses in lymphoid neoplasia
Xiaoguang Wang, Canping Chen, Dan Vuong, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1324-1335
Open Access | Times Cited: 8
Reshaping the tumor microenvironment: The versatility of immunomodulatory drugs in B-cell neoplasms
Hao Guo, Jingyi Yang, Haoran Wang, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 13
Updates of primary central nervous system lymphoma
Jiaying Wu, Delian Zhou, Xiaojian Zhu, et al.
Therapeutic Advances in Hematology (2024) Vol. 15
Open Access | Times Cited: 2
Emerging Therapeutic Targets and Drug Resistance Mechanisms in Immunotherapy of Hematological Malignancies
Wioletta Olejarz, Grzegorz Basak
Cancers (2023) Vol. 15, Iss. 24, pp. 5765-5765
Open Access | Times Cited: 6
Targeted protein degradation: from small molecules to complex organelles—a Keystone Symposia report
Jennifer Cable, Eilika Weber‐Ban, Tim Clausen, et al.
Annals of the New York Academy of Sciences (2022) Vol. 1510, Iss. 1, pp. 79-99
Open Access | Times Cited: 8
High-Throughput CRISPR Screening in Hematological Neoplasms
Raquel Ancos-Pintado, Irene Bragado-García, María Luz Morales, et al.
Cancers (2022) Vol. 14, Iss. 15, pp. 3612-3612
Open Access | Times Cited: 8
Population pharmacokinetics of lenalidomide in Chinese patients with influence of genetic polymorphisms of ABCB1
Xiao‐Xiao Liang, Haiyan Shi, Kehong Bi, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
SOHO State of the Art Updates and Next Questions: Managing Relapsed Mantle Cell Lymphoma
Jason T. Romancik, Drew G. Gerber, Tony Zhuang, et al.
Clinical Lymphoma Myeloma & Leukemia (2022) Vol. 22, Iss. 8, pp. 557-565
Closed Access | Times Cited: 6
New hopes in relapsed refractory primary central nervous system lymphoma
Teresa Calimeri, Carolina Steidl, Paolo Del Fiore, et al.
Current Opinion in Oncology (2023) Vol. 35, Iss. 5, pp. 364-372
Closed Access | Times Cited: 2
Page 1 - Next Page

Scroll to top